CIHR/Rx&D Collaborative Research Program
In partnership with
The Canadian Lung Association (CLA)
The Canadian Thoracic Society (CTS)
The CIHR Institute of Circulatory and Respiratory Health (ICRH)
GlaxoSmithKline Inc. (GSK)
| Important Dates | |
| Opportunity Launched | September 2006 |
| Content Last Updated | (No updates since launch) |
| January 1, 2007 | Full applications must be courier stamped by this date. |
| January 31, 2007 | Relevancy review will be completed by this date. |
| April 30, 2007 | Peer review will be completed by this date. |
| May 31, 2007 | Notification of decision will be completed by this date. |
| September 1, 2007 | Earliest start date. |
| Additional Information | Applicants must choose the most appropriate CIHR research training award program for which they are eligible and may only submit an application to one of these programs. Applicants must wait until after they are notified of the decision for one application before they can submit to another training award opportunity. |
| Funds Available: | |
| CIHR's contribution to the amount available for this initiative is subject to availability of funds voted annually to CIHR by parliamentary appropriations, and the conditions that may be attached to them.
The maximum amount awarded for a single award is $120,000 for up to 2 years:
| |
| Summary | |
|
The purpose of this funding opportunity is to build Canadian capacity and expertise in the area of respiratory health and to promote excellence in research through training awards. | |
Background
Partners
Objectives
Eligibility
Allowable Costs
Review Process and Evaluation Criteria
General CIHR Guidelines
Conditions of Funding
Communications Requirements
Monitoring, Performance Measurement and Evaluation
How to Apply
Contact Information
Description of Partners
The priority for this fellowship competition will focus upon the study of airflow obstruction and the associated diseases of airflow obstruction. This funding will be aimed at improving Canadian research into the pathophysiology, cell biology, population health and health systems research focussed upon diseases such as asthma and COPD.
CIHR's Research Translation Programs Branch is dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative. Applicants are invited to visit the Descriptions of Partners to find a list of partners and their respective mandates and/or strategic interests. This list will continue to evolve as new partners join in this initiative. The specific research foci and requirements for each partner are outlined in the section "Objectives."
The specific objective of this initiative is:
In addition, the intent of this initiative is to facilitate the translational objectives of CIHR, with particular interests in clinical research. Clinical research combines discoveries from the basic science laboratory incorporating the observations and insights of health professionals (a key aspect of translational research). It is the creation of new health knowledge and the translation of that knowledge from the research setting into applications where it ultimately impacts on the health of Canadians.
Relevant Research Areas
Relevant research areas include:
Examples of research that might be conducted under this Request for Applications are provided below. These examples are not intended to be exhaustive and there is no intent to imply that applications in these research areas would be more successful than those in other research areas.
Funding will be provided for applications that are relevant to (in alignment with) the objectives and research priority areas described above.
Prior to peer review, CIHR, CLA, CTS and GSK will have access to anonymized project titles and summaries to conduct relevance review.
The following criteria will be used in conducting the relevance review:
Upon completion of peer review, CLA and GSK will receive the ranking list, merit scores (ratings) and recommendations of the peer review committee with regards to funding level and award term, for the submitted applications that fall in the fundable range and have been determined to be relevant to the specific research areas and objectives of the initiative. The list will be used for funding decision-making purposes and will remain anonymous.
The review of applications for relevance to the strategic initiative will have no impact on the peer review process.
Eligibility criteria for all CIHR research funding programs apply. The business office of the institution of an eligible Nominated Principal Applicant generally administers CIHR funds. Please refer to the Eligibility Requirements for CIHR Grants and Awards regarding the eligibility requirements for individuals and institutions.
Specific to CIHR industry-partnered programs, please refer to the General Guidelines for Industry-Partnered Programs.
Specific to CIHR training awards, please refer to the General Guidelines for Training Programs as well as the Fellowships: Industry Partnered program description.
The awards consist of a stipend and a research allowance.
For the research allowance, awardees should review the Tri-Agency (CIHR, NSERC and SSHRC) financial administration guidelines, Use of Grant Funds section for a complete listing and description of allowable costs and activities.
A CIHR peer review committee will evaluate the full applications. The committee may be drawn from a CIHR's pre-existing committee or may be created specifically for this Request for Applications. Committee members are selected based on suggestions from many sources including the institute(s) / portfolio(s) and partner(s), following CIHR's Policy on Confidentiality, Conflict of Interest and Privacy Issues in Peer and Relevance Review (CCIP). Fellowship Awards are reviewed in accordance with the Guide for Reviewer - CIHR Fellowships.
The following general criteria for evaluating Fellowship Award applications will be used:
This Request for Applications will follow the CIHR General Grants and Awards Policies. Applicants are encouraged to demonstrate the use of Gender and Sex-Based Analysis in applications.
All conditions specified in CIHR General Grants and Awards Policies shall apply to applications funded through this Request for Applications. Conditions cover areas such as Applicant and Institutional Responsibilities, Ethics, Official language policy, Access to Information and Privacy Acts, and Acknowledgement of CIHR Support. Successful applicants will be informed of any special financial conditions prior to the release of funds or when they receive CIHR's Authorization for Funding (AFF) document.
Access to Information Act and Privacy Act, and the Personal Information Protection and Electronic Documents Act (PIPEDA)
All personal information collected by CIHR about applicants is used to review applications, to recruit reviewers, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by CIHR may be shared as described in Use and Disclosure of Personal Information Provided to CIHR for Peer Review.
CIHR as a federal entity is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in CIHR's premises including, without limitation, cost-sharing agreements related to this Request for Applications and all matters pertaining thereto.
While respecting the application of the Privacy Act to federal entities, all signing parties involved in a collaborative agreement will also be bound by the Personal Information Protection and Electronic Documents Act (PIPEDA). All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under collaborative agreements related to the Request for Applications will be collected, used and disclosed in compliance with the PIPEDA.
Award recipients are required to acknowledge CIHR, its institutes and partners in any communication or publication related to the project. See CIHR General Grants and Awards Policies, Acknowledgement of CIHR's Support for details on CIHR's communication requirements. The contributing institutes / partners will be identified on the Authorization for Funding and decision letter.
CIHR is committed to demonstrating results to Canadians for the money invested in health research. Therefore, processes for monitoring progress and appropriate use of funds, as well as for performance measurement and program evaluation are in place. As a result, funding recipients must:
The application process is comprised of one step: Submission of Full Application.
Review the application instructions provided in How to Apply for Funding.
Select "Fellowships - Industry Partnered - Application" from the Training Programs Application Packages.
Additional instructions must be followed for this RFA.
Send the completed application package by courier to:
RE: "CIHR/CLA/GSK Fellowships in Respiratory Health"
Research Translation Programs Branch
Canadian Institutes of Health Research
Room 97, 160 Elgin Street
Address locator: 4809A
Ottawa, Ontario
K1A 0W9
For questions on CIHR funding guidelines, how to apply, and the peer review process contact:
Jacqueline Jorge
Program Delivery Officer
Canadian Institutes of Health Research
Telephone: (613) 952-5728
Fax: (613) 954-1800
E-mail: jjorge@cihr-irsc.gc.ca
Canadian Institutes of Health Research (CIHR)
CIHR is Canada's major federal funding agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.
CIHR/Rx&D Collaborative Research Program (CIHR/Rx&D) is a partnership between Canada's Research-Based Pharmaceutical Companies (Rx&D) and CIHR established to provide an opportunity for health researchers to work in collaboration with Rx&D companies. The Program enables scientists, clinicians and members of the full spectrum of health professions, and Rx&D members to optimize opportunities in clinical research benefiting the health of Canadians.
CIHR Institute of Circulatory and Respiratory Health (ICRH) supports research into causes, mechanisms, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions associated with the heart, lung, brain (stroke), blood, blood vessels, [critical care] and [sleep].
The Canadian Lung Association (CLA)
CLA's mission is to lead national and international lung health initiatives in preventing lung disease; helping people manage lung disease and promoting lung health. A unique partnership of ten provincial Lung Associations from coast to coast, the Canadian Lung Association acts to strengthen the work of the provincial associations through support of research, advocacy of improved respiratory health, communications and coordination of services.
The Canadian Thoracic Society (CTS)
The CTS is the medical section of the Canadian Lung Association. It advises the Association on scientific matters and programs including policies regarding support for research and professional education. The CTS provides a forum whereby medical practitioners and investigators may join in the study of thoracic diseases and other medical fields that may come within the scope of The Lung Association.
GlaxoSmithKline Inc. (GSK)
GSK is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
